Advances in imaging and in non-surgical salvage treatments after radiorecurrence in prostate cancer: what does the oncologist, radiotherapist and radiologist need to know?

[1] Potosky AL(2004)Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study J Natl Cancer Inst 96 1358-1367

[2] Davis WW(2003)Pre-treatment predictors of time to cancer specific death after prostate specific antigen failure J Urol 169 1320-1324

[3] Hoffman RM(1998)Modelling post-radiation PSA levels kinetics: predictors of rising postnadir slope suggest cure in men who remain biochemically free of prostate carcinoma Cancer 83 130-134

[4] D’Amico AV(2005)PSA bounces after neoadjuvant androgen deprivation and external beam radiation: impact on definitions of failure Int J Radiat Oncol Biol Phys 62 714-718

[5] Cote K(2005)Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated by external beam radiation alone: a multi-institutional pooled analysis J Urol 173 797-802

[6] Loffredo M(2008)The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer Cancer 112 55-60

[7] Hanlom AL(2012)Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials Lancet Oncol 13 189-195

[8] Moore DF(1995)Prostate specific antigen after radiotherapy for prostate cancer: a reevaluation of long-term biochemical control and the kinetics of recurrence in patients treated at Stanford University J Urol 154 1412-1417

[9] Hanks GE(2010)Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy BJU Int 105 191-201

[10] Zietman AL(2011)Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy BJU Int 108 1074-1085

[1] Potosky AL(2004)Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study J Natl Cancer Inst 96 1358-1367

[2] Davis WW(2003)Pre-treatment predictors of time to cancer specific death after prostate specific antigen failure J Urol 169 1320-1324

[3] Hoffman RM(1998)Modelling post-radiation PSA levels kinetics: predictors of rising postnadir slope suggest cure in men who remain biochemically free of prostate carcinoma Cancer 83 130-134

[4] D’Amico AV(2005)PSA bounces after neoadjuvant androgen deprivation and external beam radiation: impact on definitions of failure Int J Radiat Oncol Biol Phys 62 714-718

[5] Cote K(2005)Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated by external beam radiation alone: a multi-institutional pooled analysis J Urol 173 797-802

[6] Loffredo M(2008)The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer Cancer 112 55-60

[7] Hanlom AL(2012)Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials Lancet Oncol 13 189-195

[8] Moore DF(1995)Prostate specific antigen after radiotherapy for prostate cancer: a reevaluation of long-term biochemical control and the kinetics of recurrence in patients treated at Stanford University J Urol 154 1412-1417

[9] Hanks GE(2010)Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy BJU Int 105 191-201

[10] Zietman AL(2011)Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy BJU Int 108 1074-1085